GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2007

Advancement of Respiratory Disease Drug Triggers $1M Payment to Pharmacopeia

  • Schering-Plough’s initiation of human trials prompted a $1 million payment to Pharmacopeia. The compound, PS948115, identified through the firms’ partnership, is being evaluated as a treatment for respiratory disease.

    “The Schering-Plough collaboration continues to yield very attractive therapeutic candidates,” points out Les Browne, Ph.D., president and CEO of Pharmacopeia. In March the companies reported Phase I evaluation of an anti-inflammatory compound and in April they selected another candidate for preclinical evaluation.

    Schering-Plough is solely responsible for further development and commercialization. Pharmacopeia is eligible to receive additional milestone payments depending on development success and royalties on resulting products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?